Quantessence Capital LLC Invests $555,000 in DexCom, Inc. (NASDAQ:DXCM)

Quantessence Capital LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 7,132 shares of the medical device company's stock, valued at approximately $555,000.

Other hedge funds have also recently made changes to their positions in the company. Eversept Partners LP acquired a new stake in DexCom in the 4th quarter valued at about $11,563,000. Stifel Financial Corp increased its holdings in shares of DexCom by 8.8% in the 4th quarter. Stifel Financial Corp now owns 101,013 shares of the medical device company's stock valued at $7,856,000 after acquiring an additional 8,142 shares during the period. OneDigital Investment Advisors LLC raised its holdings in shares of DexCom by 2.6% in the fourth quarter. OneDigital Investment Advisors LLC now owns 60,272 shares of the medical device company's stock valued at $4,687,000 after buying an additional 1,548 shares during the last quarter. Thematics Asset Management lifted its position in DexCom by 4.3% during the 4th quarter. Thematics Asset Management now owns 256,729 shares of the medical device company's stock worth $19,966,000 after acquiring an additional 10,556 shares during the period. Finally, Sharpepoint LLC acquired a new position in DexCom in the 4th quarter valued at $343,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and increased their target price for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Mizuho began coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price on the stock. Citigroup lifted their price target on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Cfra Research upgraded DexCom to a "hold" rating in a research report on Friday, March 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $99.00.

Insider Activity

In other news, EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,009 shares of company stock valued at $8,044,178. Insiders own 0.32% of the company's stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $66.33 on Wednesday. The company has a market capitalization of $26.01 billion, a price-to-earnings ratio of 46.38, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $139.24. The business has a 50 day simple moving average of $74.27 and a 200-day simple moving average of $76.66. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.